Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.68 |
| ▸ | GLP1R | P43220 | 6/20 | 0.63 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.61 |
| ▸ | ECE1 | P42892 | 1/20 | 0.61 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.61 |
| ▸ | BACE1 | P56817 | 1/20 | 0.60 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.60 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.59 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30721553 | 0.97 | TFPI (0.66) | TFPIGLP1RVIPR1ECE1MUS81 | |
| SCHEMBL30836920 | 0.96 | TFPI (0.66) | TFPIGLP1RVIPR1ECE1MUS81 | |
| SCHEMBL30120636 | 0.96 | TFPI (0.66) | TFPIGLP1RVIPR1BACE1BACE2 | |
| SCHEMBL30721600 | 0.96 | TFPI (0.64) | TFPIGLP1RVIPR1ECE1MUS81 | |
| SCHEMBL30271991 | 0.94 | TFPI (0.66) | TFPIGLP1RVIPR1ECE1MUS81 | |
| SCHEMBL30874390 | 0.94 | TFPI (0.63) | TFPIGLP1RVIPR1ECE1MUS81 | |
| SCHEMBL30467092 | 0.94 | TFPI (0.62) | TFPIGLP1RVIPR1OPRM1OPRD1 | |
| SCHEMBL29376362 | 0.94 | TFPI (0.66) | TFPIGLP1RVIPR1ECE1MUS81 | |
| SCHEMBL30271990 | 0.93 | TFPI (0.67) | TFPIGLP1RVIPR1ECE1MUS81 | |
| SCHEMBL29373287 | 0.93 | TFPI (0.66) | TFPIGLP1RVIPR1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-07-26 | — | — | US | claimed |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-02-10 | — | — | US | claimed |
| CN-119161410-A | Synthesis method of semaglutin dipeptide fragment | 质肽药业(泰州)有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-112912390-B | GLP-1 analogues and methods of preparation | 北京费森尤斯卡比医药有限公司 | 2023-12-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | GLP1R, IAPP, VIP | TFPI 525/4885GLP1R 1/4885VIPR1 37/4885 |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | GLP1R, IAPP, VIP | TFPI 525/4885GLP1R 1/4885VIPR1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.